Re-Assessing PK/PD Issues for Oral Protein and Peptide Delivery

Area of Science:

• Pharmaceutical Sciences
• Drug Delivery
• Biotechnology

Background:

• Parenteral administration is the primary route for protein and peptide therapeutics due to challenges in oral delivery.
• Recent technological advancements are enabling clinical validation of oral biopharmaceutical delivery.
• Existing pharmacokinetic (PK) and pharmacodynamic (PD) models derived from parenteral routes may not fully apply to oral delivery.

Purpose of the Study:

• To examine the discrepancies between oral and parenteral administration of protein therapeutics.
• To propose a framework for re-evaluating assessment methods for oral biopharmaceutical delivery.
• To align PK/PD outcomes with the unique characteristics of oral delivery systems.

Main Methods:

• Review of current literature on oral protein and peptide delivery technologies.
• Analysis of pharmacokinetic (PK) and pharmacodynamic (PD) data from oral versus parenteral administration.
• Comparative assessment of existing and proposed models for evaluating oral drug delivery efficacy.

Main Results:

• Oral delivery of biopharmaceuticals presents unique PK/PD profiles distinct from parenteral routes.
• Current success criteria for oral delivery may not adequately capture therapeutic effectiveness.
• Discrepancies necessitate a re-evaluation of how oral delivery performance is measured.

Conclusions:

• Established PK/PD paradigms require adaptation for oral protein and peptide therapeutics.
• Developing new models and success metrics is crucial for optimizing oral biopharmaceutical development.
• A revised approach will enhance the clinical translation and therapeutic success of oral peptide and protein drugs.